Complete Guide,Beta-Amyloid (17-42

The search keyword "american peptide 62-0-80" points to a specific product that plays a significant role in scientific research, particularly within the field of neurodegenerative diseases like Alzheimer's. This product, American Peptide 62-0-80, is a peptide that has been extensively utilized in studies focusing on amyloid beta aggregation and its implications for brain health. Understanding the nature and application of this peptide is crucial for researchers and anyone interested in the mechanisms of Alzheimer's disease.

American Peptide 62-0-80 is frequently identified as Human β-amyloid peptide (1-42). This specific peptide is a 42-amino acid fragment derived from the larger amyloid precursor protein (APP). Its significance lies in its propensity to aggregate and form amyloid plaques in the brain, a hallmark pathology associated with Alzheimer's disease. The American Peptide Company has been a key supplier of this crucial research material, with the product number 62-0-80 becoming a recognizable identifier in scientific literature.

Research involving American Peptide 62-0-80 often focuses on its aggregation properties. For instance, studies have investigated how this peptide can be prepared and manipulated for experimental purposes. One common method involves dissolving the lyophilized peptide (62-0-80, American Peptide) in hexafluoroisopropanol (HFIP). This treatment is sometimes used to prepare specific forms of the peptide, such as the disulfide-linked, stabilized form of Beta-amyloid (1-40) or to generate beta-amyloid (1-42) from American Peptide (Product #62-0-80). The preparation of beta-amyloid (1-42) (62-0-80, American Peptide) and its subsequent use in experiments highlight the direct connection between this product and the study of amyloid plaques.

The role of American Peptide 62-0-80 extends to investigating potential therapeutic strategies. Researchers utilize this peptide to model the disease, allowing them to test the efficacy of various interventions. For example, studies have explored therapeutic potential of small peptides in Alzheimer's disease by using American Peptide 62-0-80 as a benchmark for aggregation or as a target for inhibitory peptides. The American Peptide Company is thus instrumental in providing the tools necessary for these investigations.

Furthermore, the peptide itself has characteristics that make it a valuable research subject. It is described as a brain-penetrant amyloid protein fragment, which is essential for studying its behavior within the central nervous system. The molecular weight of this peptide is approximately MW 4615.19 g/mol, providing a specific parameter for its identification and quantification in experimental setups. The fact that Human β-amyloid peptide (1-42) is a peptide found in plaques in the brains of patients with Alzheimer's disease underscores its direct relevance to the disease pathology.

Various scientific publications frequently cite the use of American Peptide 62-0-80. For instance, papers mention the preparation of Abeta oligomers using beta-amyloid (1-42) from American Peptide (Product #62-0-80) for research purposes. The American Peptide Company, catalog number 62-0-80, is a consistent reference point in experimental protocols. This indicates that American Peptide Company is a trusted source for this critical research peptide.

The scientific community also refers to related peptides and their properties, which further contextualize the importance of American Peptide 62-0-80. For example, discussions around Beta-Amyloid (17-42) and Amyloid beta-peptide (12-28), human highlight the broader family of amyloid beta fragments and their roles in research. While these may be different peptides, their study often complements research involving American Peptide 62-0-80.

In summary, American Peptide 62-0-80 is a vital research peptide, specifically Human β-amyloid peptide (1-42), supplied by the American Peptide Company. Its consistent citation in scientific literature, particularly in studies related to Alzheimer's disease and amyloid beta aggregation, highlights its indispensable role in advancing our understanding of neurodegenerative disorders and in the development of potential therapeutic interventions. The peptide's properties as a brain-penetrant amyloid protein fragment and its presence in amyloid plaques make it a cornerstone for researchers in this critical field.